ACELRX PHARMACEUTICALS INC's ticker is ACRX and the CUSIP is 00444T100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $4,750,000 | +114.0% | 1,032,715 | 0.0% | 0.20% | +92.3% |
| Q2 2017 | $2,220,000 | -31.8% | 1,032,715 | 0.0% | 0.10% | -32.5% |
| Q1 2017 | $3,253,000 | +21.2% | 1,032,715 | 0.0% | 0.15% | +0.7% |
| Q4 2016 | $2,685,000 | -57.8% | 1,032,715 | -36.8% | 0.15% | -58.5% |
| Q3 2016 | $6,359,000 | +65.9% | 1,634,608 | +14.7% | 0.37% | +27.2% |
| Q2 2016 | $3,834,000 | -12.7% | 1,425,439 | 0.0% | 0.29% | -15.0% |
| Q1 2016 | $4,390,000 | -20.0% | 1,425,439 | 0.0% | 0.34% | +11.8% |
| Q4 2015 | $5,488,000 | +8.6% | 1,425,439 | -14.0% | 0.30% | +25.5% |
| Q3 2015 | $5,053,000 | -44.2% | 1,656,644 | -22.4% | 0.24% | -39.7% |
| Q2 2015 | $9,056,000 | +9.8% | 2,135,739 | 0.0% | 0.40% | -1.2% |
| Q1 2015 | $8,244,000 | -42.5% | 2,135,739 | +0.3% | 0.41% | -51.5% |
| Q4 2014 | $14,325,000 | +60.8% | 2,128,539 | +31.2% | 0.84% | +26.3% |
| Q3 2014 | $8,908,000 | – | 1,622,654 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 6,574,060 | $44,243,000 | 3.71% |
| SENZAR ASSET MANAGEMENT, LLC | 906,781 | $6,103,000 | 1.79% |
| Cormorant Asset Management, LP | 1,000,000 | $6,730,000 | 1.04% |
| Palo Alto Investors LP | 2,128,539 | $14,325,000 | 0.84% |
| Opus Point Partners Management, LLC | 99,959 | $673,000 | 0.67% |
| Granahan Investment Management | 1,541,984 | $10,378,000 | 0.30% |
| Joel Isaacson & Co., LLC | 135,660 | $913,000 | 0.24% |
| MORGENS WATERFALL VINTIADIS & CO INC | 63,700 | $429,000 | 0.24% |
| WALL STREET ASSOCIATES | 367,200 | $2,471,000 | 0.24% |
| SHEPHERD KAPLAN KROCHUK, LLC | 214,784 | $1,445,000 | 0.23% |